drugset / Trial / NCT07354022
A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the efficacy and safety of HRS-8080 combined with dalpiciclib versus fulvestrant combined with dalpiciclib in patients with locally advanced/metastatic breast cancer who had developed drug resistance to prior adjuvant endocrine therapy.
Timeline
- Start
- 2026-05-05
- Primary completion
- 2028-12
- Completion
- 2031-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fulvestrant | Small molecule | — | — |
| Subject | HRS-8080 | Unknown | — | — |
| Background | Dalpiciclib | Small molecule | — | — |